NASA rates food and nutrition as Gap #0305: Priority 9 of 58 in the Moon-to-Mars Architecture. ORCA is the only commercial system designed to fill it. Three space agencies have made unsolicited inbound contact. Peer-reviewed in npj Microgravity. Patent-protected.

75% of long-duration astronauts develop progressive vision loss. Zero approved countermeasures.

These are not edge cases. Every deficit compounds over a 600-day Mars transit. After 120 days, the Third-Quarter Phenomenon triggers 15-20% cognitive decline. Crew performance degrades at exactly the moment missions get hardest. No food system in orbit addresses the root cause: the total absence of fresh, bioactive nutrition.

Fits a standard ISS EXPRESS rack (0.24 m³). Fully automated: under 20 minutes crew time per week. Continuous 10-day growth cycle producing CRISPR-optimized broccoli microgreens. 37 harvests per year, per unit.

In practical terms: line up 100 people with this intervention and 100 without. 97 of the treated group show better cellular protection. Most drugs consider d = 0.8 "large." This is more than double that threshold.

Model R² = 0.71  |  k = 28 peer-reviewed studies

Once a CRISPR-optimized cultivar is validated in space, that same crop grows in every unit, on every station, at zero marginal R&D cost. The IP licenses across space stations, terrestrial vertical farms, arid agriculture, and nutraceuticals simultaneously. One validation, unlimited deployment.

ISS retires by 2030. Four replacement stations in development. Subsystem integration decisions are finalizing now, in 2026-2027. Miss this window and the architecture locks without biological ECLSS. No commercial operator has budgeted for it yet. The procurement gap is wide open.

"No one mentioned a commercial competitor to Gastronaut."

"Gotham Greens has already contacted Gastronaut."

The terrestrial engine grows independently of station timelines. Space validates; Earth scales. Combined projection: $60M+ revenue by 2032 at 75% gross margins.

Platform valuation: $600M-$900M at scale

Grounded in observed transaction data. Mission-critical space infrastructure with recurring revenue commands 8-15x multiples. The biotech premium (15-25x) drives the aggressive scenario past $1B. Comparable exits: Ginkgo Bioworks $17.5B, Plenty $4.1B, Planet Labs $2.8B.

"Generic antioxidants already failed. There is no shortcut."

A competitor entering today needs 2-3 years of growth cycles, separate CRISPR development, ICP-MS validation, and a peer-reviewed publication track. By then, station integration windows will have closed. The moat is not just science. It is time.

The Canadian Space Agency sent a formal letter urging Brian to protect this idea. Three agencies initiated contact independently, before any outreach. Prior exit experience, deep technical credibility, and agency relationships most seed-stage companies spend years building.

Every dollar maps to a de-risking milestone. CRISPR IP filing secures the cultivar portfolio. HERA analog validation generates peer-reviewed data that unlocks SBIR funding and station operator MOUs. Each milestone de-risks the next round.